Astrazeneca Pharma India Ltd is Rated Sell

Current Rating and Its Significance

The 'Sell' rating assigned to Astrazeneca Pharma India Ltd indicates a cautious stance for investors considering this stock. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. The rating suggests that, given the current market and company conditions, investors may want to consider reducing exposure or avoiding new positions in this stock until there is a clearer sign of improvement.

Quality Assessment

As of 26 September 2026, Astrazeneca Pharma India Ltd maintains a good quality grade. This reflects the company’s solid operational foundation and consistent business model within the Pharmaceuticals & Biotechnology sector. The company’s return on equity (ROE) stands at a robust 19.9%, signalling effective utilisation of shareholder capital. Despite this, the quality grade alone is not sufficient to offset other concerns impacting the overall rating.

Valuation Perspective

The stock is currently classified as very expensive based on valuation metrics. Trading at a price-to-book (P/B) ratio of 18.7, Astrazeneca Pharma India Ltd is priced at a significant premium compared to its peers and historical averages. This elevated valuation implies that the market expects strong future growth, which, as current data suggests, is not being realised. Investors should be wary of paying a high premium when the company’s recent financial trends do not fully support such optimism.

Financial Trend Analysis

The financial trend for Astrazeneca Pharma India Ltd is currently flat. The latest results show a decline in profitability and cash flow generation. Specifically, profit before tax (PBT) excluding other income for the quarter ending June 2026 fell by 27.0% compared to the previous four-quarter average, registering at ₹41.76 crores. Operating cash flow for the year is notably weak, with a negative ₹15.14 crores, indicating challenges in converting earnings into cash. Additionally, the company’s profit after tax (PAT) over the latest six months has decreased by 29.3%, standing at ₹83.82 crores. These figures highlight a period of stagnation and contraction rather than growth.

Technical Outlook

From a technical standpoint, Astrazeneca Pharma India Ltd is rated bearish. The stock has underperformed significantly over multiple time frames. As of 26 September 2026, the stock’s returns are negative across all key periods: a 1-day decline of 1.08%, 1-week down 3.46%, 1-month down 9.05%, 3-month down 22.25%, 6-month down 22.55%, year-to-date down 27.66%, and a 1-year return of -27.83%. This underperformance is stark when compared to the broader BSE500 index, which itself posted a negative return of -2.22% over the past year. The technical indicators suggest persistent selling pressure and weak investor sentiment.

Market Capitalisation and Sector Context

Astrazeneca Pharma India Ltd is classified as a small-cap stock within the Pharmaceuticals & Biotechnology sector. Small-cap stocks often carry higher volatility and risk, which is reflected in the stock’s recent performance and valuation premium. The sector itself is competitive and subject to regulatory and innovation-driven challenges, which may be contributing to the company’s current financial and technical difficulties.

Investor Implications

For investors, the 'Sell' rating signals caution. While the company demonstrates good quality fundamentals, the very expensive valuation combined with flat financial trends and bearish technicals suggest limited upside potential in the near term. Investors should carefully consider whether the current price justifies the risks, especially given the stock’s significant underperformance relative to the market and peers.

Summary of Key Metrics as of 26 September 2026

• Mojo Score: 37.0 (Sell Grade)
• ROE: 19.9%
• Price to Book Value: 18.7 (Very Expensive)
• Profit Before Tax (excl. other income, quarterly): ₹41.76 crores, down 27.0%
• Operating Cash Flow (yearly): -₹15.14 crores
• Profit After Tax (latest six months): ₹83.82 crores, down 29.3%
• Stock Returns (1Y): -27.83%
• Sector: Pharmaceuticals & Biotechnology

Conclusion

In conclusion, Astrazeneca Pharma India Ltd’s current 'Sell' rating reflects a combination of strong quality fundamentals overshadowed by an expensive valuation, flat financial trends, and bearish technical signals. Investors should approach this stock with caution, recognising the risks posed by its recent underperformance and valuation premium. Monitoring future quarterly results and market developments will be crucial to reassessing the stock’s outlook.

Understanding the Rating

The 'Sell' rating from MarketsMOJO is a clear indication that the stock is expected to underperform relative to the broader market or its sector peers in the near term. This rating is designed to help investors make informed decisions by highlighting stocks where the risk-reward balance currently favours caution. It does not imply an immediate sell-off but rather suggests that investors should consider reducing holdings or avoiding new purchases until conditions improve.

Looking Ahead

Investors interested in Astrazeneca Pharma India Ltd should keep a close eye on upcoming earnings releases, cash flow improvements, and any shifts in valuation multiples. Additionally, sector-wide trends in Pharmaceuticals & Biotechnology, including regulatory changes and innovation cycles, will play a significant role in shaping the company’s future prospects.

Final Note

While the company’s quality remains good, the combination of very expensive valuation, flat financial performance, and bearish technicals underpin the current 'Sell' rating. This comprehensive view aims to equip investors with a balanced understanding of Astrazeneca Pharma India Ltd’s present standing in the market.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →